| pubmed-article:3006858 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3006858 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:3006858 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:3006858 | lifeskim:mentions | umls-concept:C0034798 | lld:lifeskim |
| pubmed-article:3006858 | lifeskim:mentions | umls-concept:C0005823 | lld:lifeskim |
| pubmed-article:3006858 | lifeskim:mentions | umls-concept:C0018810 | lld:lifeskim |
| pubmed-article:3006858 | lifeskim:mentions | umls-concept:C0441994 | lld:lifeskim |
| pubmed-article:3006858 | lifeskim:mentions | umls-concept:C1948023 | lld:lifeskim |
| pubmed-article:3006858 | lifeskim:mentions | umls-concept:C0052855 | lld:lifeskim |
| pubmed-article:3006858 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3006858 | pubmed:dateCreated | 1986-5-1 | lld:pubmed |
| pubmed-article:3006858 | pubmed:abstractText | To investigate whether the hypotensive and bradycardiac effects of B-HT 958 (2-amino-6-(p-chlorobenzyl)-4H-5,6,7,8-tetrahydrothiazolo-(5,4-d) azepine) are due to the stimulation of peripheral prejunctional alpha2-adrenoceptors, the selective alpha2-adrenoceptor antagonist idazoxan was given either intravenously (i.v.) or intracerebroventricularly (i.c.v.) to anaesthetized rats before the administration of i.v. B-HT 958. Plasma noradrenaline was used as an approximate index of peripheral sympathetic nervous activity. B-HT 958 350 micrograms kg-1 i.v. caused significant falls in blood pressure and heart rate which were maximal 5 min after dosing (-29.25 +/- 3.2 mmHg and - 52 +/- 6.8 beats min-1 respectively, mean of all control animals). The hypotension and bradycardia were accompanied by significant falls in plasma noradrenaline concentration of 30-40%. Idazoxan 300 micrograms kg-1 i.v. caused a marked, but transient tachycardia and a large sustained rise in plasma noradrenaline concentration. Idazoxan 300 micrograms kg-1 and 1000 micrograms kg-1 i.v. did not prevent B-HT 958-induced falls in mean arterial pressure, heart rate and plasma noradrenaline concentration. Responses to B-HT 958 were unaffected by idazoxan 20 micrograms i.c.v. B-HT 958-induced falls in mean arterial pressure, heart rate and plasma noradrenaline concentration were significantly attenuated by i.v. administration of the dopamine receptor antagonist, sulpiride 300 micrograms kg-1. Sulpiride 10 micrograms and 50 micrograms i.c.v. caused inhibition of B-HT 958 hypotension and bradycardia similar to that of intravenous sulpiride. After i.c.v. sulpiride, B-HT 958 did not cause a significant fall in plasma noradrenaline concentration. A combination of idazoxan 1000 micrograms kg-1 i.v. and sulpiride 300 micrograms kg-1 i.v. did not cause further significant inhibition of B-HT 958 hypotension and bradycardia compared with sulpiride 300 micrograms kg-1 i.v. alone. This combination however had a significantly greater effect in inhibiting B-HT 958 hypotension than had idazoxan 1000 micrograms kg-1 alone, and almost completely blocked the B-HT 958-induced fall in plasma noradrenaline concentration. These results suggest that in the anaesthetized rat the cardiovascular effects of B-HT 958 are due to stimulation of dopamine receptors, probably located within the central nervous system, and not to stimulation of peripheral prejunctional alpha2-adrenoceptors. | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3006858 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3006858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3006858 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3006858 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:3006858 | pubmed:issn | 0007-1188 | lld:pubmed |
| pubmed-article:3006858 | pubmed:author | pubmed-author:BrownM JMJ | lld:pubmed |
| pubmed-article:3006858 | pubmed:author | pubmed-author:HarlandDD | lld:pubmed |
| pubmed-article:3006858 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3006858 | pubmed:volume | 87 | lld:pubmed |
| pubmed-article:3006858 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3006858 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3006858 | pubmed:pagination | 361-70 | lld:pubmed |
| pubmed-article:3006858 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:meshHeading | pubmed-meshheading:3006858-... | lld:pubmed |
| pubmed-article:3006858 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3006858 | pubmed:articleTitle | B-HT 958 lowers blood pressure and heart rate in the rat through stimulation of dopamine receptors. | lld:pubmed |
| pubmed-article:3006858 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3006858 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3006858 | lld:pubmed |
